ResMed Inc. is a global medical technology company specializing in the development and distribution of devices and software solutions focused on respiratory health, particularly sleep apnea and other breathing disorders. Operating within the Healthcare sector's Medical Instruments & Supplies industry, ResMed offers a range of diagnostic devices, cloud-based platforms for remote patient monitoring, and software solutions to enhance patient engagement and compliance.
ResMed has demonstrated consistent performance in its recent reported quarters. In Q3 2025, the company reported EPS of $2.55, meeting the analyst estimate of $2.49874, with revenue at $1.336 billion, slightly below the estimate of $1.3356 billion. This followed Q2 2025, where EPS was $2.55, exceeding the estimate of $2.48121, and revenue was $1.348 billion. Prior to this, Q1 2025 saw EPS of $2.37, narrowly beating the estimate of $2.36021, with revenue at $1.292 billion. The company's Q4 2024 results showed an EPS of $2.43, surpassing the estimate of $2.31463.
Historically, ResMed has shown a strong track record of meeting or exceeding analyst estimates for both EPS and revenue. The company has consistently delivered positive year-over-year growth, indicating a stable upward trajectory in its financial performance. The pattern of performance suggests a reliable business model with predictable earnings, making it a steady performer in the medical technology space.
Recent news indicates that Citigroup has maintained its 'Buy' rating on ResMed while slightly lowering its price target to $340 from $345, suggesting continued analyst optimism. Concurrently, a notable insider sale of shares valued at over $1.1 million has occurred, which warrants investor attention for further context. These developments present a mixed sentiment, with analysts remaining largely positive while insider activity requires monitoring.
Looking ahead, investors will be watching for any further analyst commentary or company updates that could influence the current positive sentiment. Key will be monitoring any additional insider transactions and understanding the underlying rationale for such activity. The company's ability to sustain its growth trajectory and analyst support will be important factors to observe in the upcoming quarters.
